Edwards Lifesciences (EW) Earnings Date & Reports

Key Takeaways

• Edwards Lifesciences is scheduled to report third-quarter 2026 results after the market closes on Wednesday, November 4, 2026, followed by a conference call at 5:00 p.m. ET.
• Management has guided third-quarter total sales of $1.63 billion to $1.71 billion and adjusted earnings per share (EPS) of $0.71 to $0.77.
• Wall Street consensus points to revenue near $1.69 billion and adjusted EPS of roughly $0.74, according to estimates compiled by Zacks.
• In the second quarter of 2026, sales rose 13.6% to $1.74 billion, with adjusted EPS of $0.78, topping estimates and prompting an increase in full-year guidance.
• Investors will focus on TAVR (transcatheter aortic valve replacement) growth and the rapid ramp of TMTT (transcatheter mitral and tricuspid therapies).
• Recent catalysts, including an expanded CMS (Centers for Medicare & Medicaid Services) coverage decision for TAVR and the FDA (U.S. Food and Drug Administration) approval of the AUTUS pediatric valve, set the backdrop for the report.

Earnings Context and Why It Matters

Edwards Lifesciences is the leading global structural heart company, and its quarterly results are a closely watched barometer for the broader medical-device sector. The stock has pulled back in recent months even as the company has raised its full-year 2026 outlook twice, creating a setup where the third-quarter print must validate management's upgraded growth assumptions. Because TAVR represents the bulk of revenue, procedure-volume trends and the response to the CMS national coverage determination (NCD) are central to the investment case. Meanwhile, the fast-growing TMTT franchise is viewed as a key long-term growth engine. This report will test whether Edwards can sustain double-digit expansion while protecting margins.

Earnings Expectations

Edwards has guided third-quarter 2026 total sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77. Consensus estimates compiled by Zacks sit near $1.69 billion for revenue and $0.74 for adjusted EPS, with TipRanks reporting a similar $0.74 consensus EPS figure. For context, a year earlier the company posted third-quarter sales of approximately $1.55 billion.

These targets follow a strong second quarter, when revenue climbed 13.6% to $1.74 billion and adjusted EPS reached $0.78, beating the consensus estimate. Within that period, TAVR sales grew 11.3% to $1.26 billion, while TMTT sales surged 47.3% to about $195.9 million. Management subsequently raised full-year 2026 sales-growth guidance to 10% to 11% (constant currency) and reaffirmed adjusted EPS guidance of $2.95 to $3.05. Investors will watch whether the third quarter keeps Edwards on track toward those annual targets.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking the medical-device sector and names like Edwards Lifesciences, the AI Screener offers a structured way to surface comparable opportunities across the industry.

Market Reaction and Investor Sentiment

Sentiment heading into the report is cautious but improving. Edwards shares have faced pressure in recent months, trading below the levels reached earlier in 2026, despite consecutive quarters of raised guidance. The September update of the CMS national coverage determination for TAVR removed a key policy overhang by broadening patient access, which analysts broadly viewed as a positive for procedure volumes. However, the subsequent share pullback suggests investors are still weighing how coverage changes will translate into case volumes and pricing. Heading into the November 4 release, the market will be looking for confirmation that TAVR growth remains resilient and that TMTT is scaling toward the company's $760 million to $780 million full-year sales target. Any sign of margin compression or slower-than-expected TAVR adoption could weigh on the stock, while a beat-and-raise would likely reinforce recent constructive analyst commentary.

Forward Outlook and Key Factors to Monitor

Following the third-quarter report, investors should track several themes that will shape Edwards' trajectory into 2027. First is the durability of TAVR growth. With the expanded CMS coverage now in place, the key question is whether procedural volumes accelerate as more patients gain access to earlier treatment for severe aortic stenosis. Management has guided full-year TAVR sales of $4.75 billion to $5.0 billion, and any commentary on adoption trends will be closely parsed.

Second, the TMTT franchise remains a focal point. Edwards expects $760 million to $780 million in TMTT sales in 2026, and continued scaling of EVOQUE, PASCAL, and SAPIEN M3 will determine whether the company remains on its stated path toward $2 billion in TMTT revenue by 2030.

Third, investors should watch margin and tax-rate dynamics. Management has signaled that the effective tax rate may land at the high end of its 16% to 19% range, and gross margin is expected to be at the lower end of the 78% to 79% full-year band, largely due to foreign-exchange effects. Finally, the company's December 2026 investor conference is expected to introduce 2027 and longer-term guidance, making the third-quarter call an important bridge to those updated targets.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations